purposeThe objective of this study is to evaluate the safety profile of Adalimumab for Hidradenitis Suppurativa (HS) participants in normal medical practice.
|Study type(s)||Observational study, Interventional|
|Study start date||01-Feb-17|
|Estimated primary completion date||01-Mar-19|
An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.
A Phase 3, Open-Label Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Hidradenitis Suppurativa - PIONEER (Open-Label Extension)
Hidradenitis Suppurativa is a painful, chronic skin disease characterized by recurrent inflamed nodules and abscesses, which may rupture to form fistulas and subsequent scarring.
Safety and Efficacy of Humira (Adalimumab) for Hidradenitis Suppurativa (HS) Peri-Surgically (SHARPS Study) (SHARPS)
The objective of this study is to assess the safety and efficacy of adalimumab prior to surgery in subjects with moderate to severe Hidradenitis Suppurativa (HS) who are surgical candidates.
To Assess the Efficacy and Safety of Adalimumab in Subjects With Moderate to Severe Hidradenitis Suppurativa (HIDRI2007)
The trial is a 12-week phase 2 study. Subjects will be given subcutaneous injections at weeks 0 (160mg), 2 (80mg), and then every other week (40mg)
A Randomized, Double-blind, Placebo Controlled, Multicenter Regimen Finding Study of Subcutaneously Administered AIN457, Assessing Psoriasis Area and Severity Index (PASI) Response in Patients With Moderate to Severe Chronic Plaque-type Psoriasis
The purpose of the study is to determine whether, in patients with moderate to severe plaque-type psoriasis, AIN457 administered subcutaneously reduces the severity of psoriasis symptoms and the extent...
A Dose-Ranging And Efficacy Study of LY2439821 (An Anti-IL-17 Antibody) In Patients With Moderate-To-Severe Psoriasis
The safety of ixekizumab (LY2439821) and any side effects that might be associated with it....
The 76th Annual Meeting of the Society for Investigative Dermatology is underway in Portland, Oregon, USA
The 76th Annual Meeting of the Society for Investigative Dermatology (SID) takes place 26─29 April in Portland, Oregon, in the United States.
EU CHMP recommends approval of Amgevita (adalimumab biosimilar) for rheumatoid arthritis, juvenile idiopathic arthritis, axial spondyloarthritis, psoriatic arthritis, psoriasis, hidradenitis suppurativa, Crohn’s disease, ulcerative colitis and uveiti-Amgen
The EU Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing...
EU Commission approves Amgevita (biosimilar adalimumab) for all indications of the originator drug.- Amgen.
Amgen has announced that the European Commission (EC) has granted marketing authorization for Amgevita (biosimilar adalimumab) in all available indications....
The European Medicines Agency (EMA) has accepted for regulatory review Marketing Authorization Applications for biosimilars to AbbVie's Humira (adalimumab) and Janssen's Remicade (infliximab).- Sandoz
Sandoz, a Novartis division, and the pioneer and global leader in biosimilar medicines announced that the European Medicines Agency (EMA)...
Sun Pharmaceutical Industries Ltd announces the FDA acceptance of the Biologics License Application (BLA) for tildrakizumab. The FDA filing acceptance...
Establishment of a European Registry for hidradenitis suppurativa/acne inversa by using an open source software
Hidradenitis suppurativa (HS) is a chronic inflammatory skin condition characterised by recurrent painful boils in flexural sites, such as the axillae and groin, that affects about 1% of the population, with onset in early adulthood.
A double-blind controlled cross-over trial of cyproterone acetate in females with hidradenitis suppurativa.
In order to examine whether anti-androgen therapy was effective in hidradenitis suppurativa (HS), ethinyloestradiol 50μg/cyproterone acetate 50mg in a reverse sequential regimen was compared with ...
Hidradenitis suppurativa (HS) is a long-standing disease with abscess and often fistula formation, predominantly in the axillae and groins.
Evidence-based recommendations on adalimumab (Humira) for treating active moderate to severe hidradenitis suppurativa in adults whose disease has not responded to conventional systemic therapy.
Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics.
Since the publication of the 2009 Canadian Guidelines for the Management of Plaque Psoriasis, significant advances have been made in determining the role of T cells in inflammatory and autoimmune diseases.